Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045455 | 0.90 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL714350 | 0.86 | MEN1 (0.43) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14761935 | 0.86 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL24496462 | 0.86 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL15185748 | 0.83 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL15185749 | 0.83 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL27052880 | 0.81 | MEN1 (0.38) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14286753 | 0.80 | — | — | |
| SCHEMBL15617410 | 0.79 | — | — | |
| SCHEMBL18349839 | 0.77 | EPHX1 (0.36) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591594-B2 | LNA-G process | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-02-28 | — | — | US | claimed |
| EP-3341479-B1 | LNA-G PROCESS | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-12-18 | — | — | EP | claimed |
| US-20190055550-A1 | LNA-G Process | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-02-21 | — | — | US | claimed |
| US-11591594-B2 | LNA-G process | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-02-28 | — | — | US | disclosed |
| US-20200318109-A1 | LNA-G Process | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-08 | — | — | US | disclosed |
| EP-3341479-B1 | LNA-G PROCESS | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-12-18 | — | — | EP | disclosed |
| US-20190055550-A1 | LNA-G Process | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-02-21 | — | — | US | disclosed |
| US-9803184-B2 | Method for immobilizing nucleic ligands | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) | 2017-10-31 | — | — | US | disclosed |
| EP-2658864-A1 | METHOD FOR IMMOBILISING NUCLEIC LIGANDS | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (Groupement d Interet public) (FR) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012090183-A1 | METHOD FOR IMMOBILISING NUCLEIC LIGANDS | LFB BIOTECHNOLOGIES (FR) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200318109-A1 | LNA-G Process | OGG1, DUT, FBL | MEN1 1317/4885KMT2A 501/4885ALDH1A1 2120/4885 |
| US-11591594-B2 | LNA-G process | OGG1, DUT, FBL | MEN1 1251/4885KMT2A 452/4885ALDH1A1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.